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It is hypothesized that during cholestasis, the liver, kidney, and intestine alter gene expression to prevent BA accumulation; enhance urinary
excretion of BA; and decrease BA absorption, respectively. To test this hypothesis, mice were subjected to either sham or bile-duct ligation (BDL)
surgery and liver, kidney, duodenum, ileum, and serum samples were collected at 1, 3, 7, and 14 days after surgery. Serum total BA concentrations
were 1–5 μmol/l in sham-operated mice and were elevated at 1, 3, 7, and 14 days after BDL, respectively. BDL decreased liver Ntcp, Oatp1a1,
1a5, and 1b2 mRNA expression and increased Bsep, Oatp1a4, and Mrp1–5 mRNA levels. In kidney, BDL decreased Oatp1a1 and increased
Mrp1–5 mRNA levels. In intestine, BDL increased Mrp3 and Ibat mRNA levels in ileum. BDL increased Mrp1, 3, 4, and 5 protein expression in
mouse liver. These data indicate that the compensatory regulation of transporters in liver, kidney, and intestine is unable to fully compensate for
the loss of hepatic BA excretion because serum BA concentration remained elevated after 14 days of BDL. Additionally, hepatic and renal Oatp
and Mrp genes are regulated similarly during extrahepatic cholestasis, and may suggest that transporter expression is regulated not to remove bile
constituents from the body, but instead to remove bile constituents from tissues.
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Bile acids (BA) are synthesized in liver and excreted via the
common bile duct into the small intestine. Once in the intestine,
they aid in the emulsification and absorption of dietary fats.
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doi:10.1016/j.bbamem.2006.10.008and most are transported into the liver via sodium-dependent
and sodium-independent transport processes, with a small
amount being excreted into urine.
Several transporters are known to transport BAs from blood
into liver and from liver into bile. BAs are transported into the
liver by the Sodium taurocholate-cotransporting polypeptide
(Ntcp) and some members of the organic anion polypeptide
transporter superfamily (Oatps), such as Oatp1a1, 1a4, and 1b2
[1]. Ntcp mediates sodium-dependent BA transport, whereas
Oatps mediate sodium-independent BA and organic anion
transport. In liver, Ntcp, Oatp1a1, Oatp1a4, and Oatp1b2 are
localized to the sinusoidal membrane [2–5].
Conversely, the bile salt export pump (Bsep) and some
members of the multidrug resistance-associated protein (Mrp)
and Organic solute transporter family aid in transport of BAs
out of the liver into either bile (i.e. Mrp2 and Bsep), or blood
(i.e. Mrp3, Mrp4, Ostα/β) [1,6–8]. In humans, Progressive
Familial Intrahepatic Cholestasis 2 is associated with mutations
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causes a milder progressive intrahepatic cholestasis and does
not impede bile flow, although it decreases biliary excretion of
hydrophobic BAs, such as taurocholate [6]. This observation
suggests that other transporters aid in the export of BAs out of
hepatocytes. Mutations in rat Mrp2 result in hyperbilirubinemia
and moderate elevation of serum BAs [10]. In humans, similar
mutations in MRP2 cause Dubin–Johnson syndrome, which is
also associated with the accumulation of conjugated bilirubin
and bile acids in blood [11,12]. In liver, Bsep and Mrp2 are
localized to the canalicular membrane to transport chemicals
from hepatocytes into bile, whereas Mrp1, 3, 4, and 5 are
localized to the basolateral membrane, mediating transport of
chemicals from liver to blood [13–18].
The mechanisms responsible for BA transport in kidney are
not nearly as well-defined or characterized as those in liver. In
rats and mice, Oatp1a1, 1a4 and Oatp1a6 mRNAs are expressed
in kidney [19–22]. Oatp1 is localized to the apical membrane of
renal proximal tubules where it is thought to aid in tubular
reabsorption of organic compounds, and is responsible for
gender differences in taurocholate excretion [23]. Mrp1, 2, 3,
and 4 mRNAs are also detected in rat and mouse kidney
[24–26]. Mrp2 and Mrp4 are localized to the apical membrane
of proximal tubules, and are thought to aid in excretion of
organic anions and BAs into urine [26].
BAs in serum are mainly recovered by enterohepatic
circulation, rather than produced via de novo synthesis in
liver [1,27]. Intestinal absorption of BAs occurs mainly in
the ileum by the ileal BA transporter (Ibat) [1]. Recently,
the heterodimeric organic solute transporter alpha-beta
(Ostαβ) has been localized to the basolateral membrane of
enterocytes in ileum and is believed to mediate bile acid
efflux into blood circulation [28]. Mrp3 is also localized to
the basolateral membrane of enterocytes, and plays a less
important role for efflux of BAs from enterocytes into blood
[29]. In a human colon cancer cell line (Caco-2), Mrp3
expression is induced by BAs via Liver receptor homologue-
1 (Lrh-1) [30].
Cholestasis is defined as decreased or impaired bile flow.
Various models exist to study intrahepatic and extrahepatic
cholestasis. In this study, common bile-duct ligation (BDL) was
employed to model extrahepatic cholestasis, which is associated
with obstruction of the bile duct and diseases such as primary
sclerosing cholangitis. After BDL, the liver accumulates BAs,
and other compounds such as bilirubin, bilirubin–glucuronide,
and eventually BA levels increase in liver, serum, and urine.
During BDL, adaptive changes in transporter expression may
occur in liver, kidney, and intestine to decrease levels of
potentially toxic BAs and other waste in blood, and decrease
absorption of BAs. For example, expression of the bile acid
uptake transporter, Ntcp, in liver is downregulated after BDL,
which is hypothesized to be a protective response to prevent
further accumulation of bile acids in liver [31–33]. Similarly,
expression of the basolateral bile acid export transporters, Mrp3
and 4, markedly increase after BDL, a response which lowers
hepatic bile acid levels by increasing efflux of bile acids out of
liver into the blood [34–36]. Studies using Mrp3- and Mrp4-null mice have demonstrated that these transporters contribute
to liver accumulation of BAs during obstructive cholestasis.
During obstructive cholestasis, liver BA levels are higher in
Mrp3-null mice and serum BA levels are lower in serum of
Mrp4-null than wild-type controls [8,35]. In addition, choles-
tasis increases Ostβ mRNA and protein expression in liver in
rats, mice, and humans, which is another potential compensa-
tory mechanism that is induced to decrease BA concentrations
in liver [7]. Ost alpha and beta mRNA and protein is increased
in patients with PBC, as well as after bile-duct ligation in the
mouse [7].
To date, there is no single published studies that thoroughly
characterize gene expression changes in the mouse BDL model.
Therefore, the purpose of this study was to provide a
comprehensive characterization of changes in the expression
of several transporters/transporter families, namely the Oatps,
Mrps, Ntcp, and Bsep in mouse liver, kidney and small intestine
after BDL.
2. Materials and methods
2.1. Animal model
Adult male C57BL/6 mice were purchased from Jackson Laboratories
(Bar Habor, ME). The mice were housed in a temperature-, light-, and
humidity-controlled environment in cages with hardwood chips. The mice
were fed Teklad Rodent Diet #8604 (Harlan Laboratories, Madison, WI) ad
libitum. Under pentobarbital-induced anesthesia (50 mg/kg, ip), the abdominal
cavity was opened and the common bile-duct was ligated with 4-0 surgical
silk, with the gall bladder intact. The abdominal muscle was sutured with
Ethicon 4-0 dissolvable suture material and the wound was closed with
surgical staples. Sham surgeries were performed by the same method, but
without BDL. Serum, liver, kidneys, duodenum, and ileum were collected 1,
3, 7, and 14 days after BDL. Tissues were snap frozen in liquid nitrogen and
stored at −70 °C until analysis. All animal studies were conducted according
to Association for Assessment and Accreditation of Laboratory Animal Care
guidelines.
2.2. Serum BA concentration
Trunk blood was collected, allowed to coagulate, and then centrifuged at
5000 rpm for 5 min. The resulting supernatant (serum) was collected for
analysis. Serum BA concentrations were quantified according to the manufac-
turer's protocol by measuring the production of formazan by the action of 3α-
hydroxysteroid dehydrogenase and diaphorase, which is directly proportional to
the BA concentration (Trinity Biotech, Wicklow, Ireland).
2.3. RNA extraction
Total RNA from liver, kidney, duodenum, and ileum tissue was extracted
using RNA Bee Reagent (Tel-Test, Inc., Friendswood, TX) according to the
manufacturer's protocol. RNA integrity was confirmed by formaldehyde-
agarose gel electrophoresis.
2.4. Branched DNA signal amplification (bDNA) assay
Mouse Ntcp, Bsep, Oatp1a1, 1a4, 1b2, 4a1, Mrp1–5, Heme Oxygenase-1
(Ho-1) mRNA were quantified using the branched signal amplification assay
(QuantiGene® High Volume bDNA Signal Amplification Kit, Genospectra,
Freemont, CA) with modifications [24,37]. Probes to detect mouse Ntcp,
Oatp1a1, 1a4, 1a5, 1b2, Mrp1–5, and Ho-1 have been described previously [38–
42]. Multiple oligonucleotide probe sets (containing capture, label, and blocker
probes) specific to a singlemRNA transcript were designed using ProbeDesigner
Fig. 1. Bile acid concentration in serum from male C57BL/6 mice 1, 3, 7, and
14 days after sham or bile-duct ligation (BDL) surgery. The data are presented as
mean+S.E.M. (n=4–7 mice). Asterisks (*) represent a statistical difference
(p<0.05) between sham and BDL groups.
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approximately 63 °C, which enabled the hybridization conditions to be held
constant (i.e. 53 °C) during each hybridization step and for each probe set. Each
probe developed using ProbeDesigner was submitted to the National Center for
Biotechnology Information for nucleotide comparison by the basic local
alignment search tool (BLASTn), to ensure minimal cross-reactivity with other
known mouse sequences and ESTs. Oligonucleotides with a high degree of
similarity (≥80%) to other mouse gene transcripts were excluded from the
design.
Total RNA (1 μg/μl; 10 μl/well) was added to each well of a 96-well plate
containing 50 μl capture hybridization buffer and 50 μl of each diluted probe set.
For each gene, total RNAwas allowed to hybridize to the probe set overnight at
53 °C. Subsequent hybridization steps were carried out per the manufacturer's
protocol, and luminescence was measured with a Quantiplex® 320 bDNA
Luminometer interfaced with Quantiplex® (Bayer Corp.-Diagnostics, Div.,
Emeryville, CA). Data Management Software Version 5.02 for analysis of
luminescence from 96-well plates. The luminescence for each well was reported
as relative light units (RLUs) per 10 μg total RNA.
2.5. Preparation of crude membrane fractions
Livers were homogenized in ST buffer (0.25 M sucrose, 10 mM Tris–HCl,
pH 7.4) and centrifuged at 100,000×g for 60 min at 4 °C. The resulting pellet
containing the crude membrane fraction was resuspended in ST buffer. Protein
concentration was determined using Bio-Rad protein assay reagents (Bio-Rad
Laboratories, Hercules, CA).
2.6. Western blot analysis of transport proteins
Membrane proteins (50 μg protein/lane) were electrophoretically resolved
without boiling using polyacrylamide gels (8% resolving, 4% stacking) and
transblotted overnight at 4 °C onto PVDF-Plus membrane (Micron Separations
Inc., Westborough, MA). Immunochemical detection of Ho-1 was performed as
previously described [43]. Immunochemical detection of Mrp1 (∼190 kDa),
Mrp2 (∼190–200 kDa), Mrp3 (∼180–190 kDa), Mrp4 (∼160–170 kDa), Mrp5
(∼160–180 kDa), and Mrp6 (∼165 kDa) protein was performed using MRPr1,
M2III-5, M3II-2, M4I-10, M5I-60, and M6II-68 antibodies, respectively [43].
Anti-Mrp antibodies were provided by George Scheffer, VU Medical Center,
Amsterdam, the Netherlands. Membranes were blocked with 1%NFDM in PBS-
Tween for 1 h and incubated for 1 h with primary antibody diluted in blocking
buffer (1:2000 for MRPr1, M3II-2, M4I-10, M6II-68, 1:600 for M2III-5, and
1:50 for M5I-60). A species-appropriate peroxidase-labeled secondary antibody
(Sigma Chemical Co., St. Louis, MO) was diluted (1:2000) in blocking buffer
and incubatedwith blots for 1 h Protein–antibody complexeswere detected using
an ECL chemiluminescent kit (Amersham Life Sciences, Arlington Heights, IL)
and exposed to Fuji Medical X-ray film (Fisher Scientific, Pittsburgh, PA). The
intensity of protein bands was quantified using the Discovery Series Quantity
One 1-D Analysis software (Biorad, Hercules, CA).
2.7. Statistics
Statistical differences between groups at each time point were determined by
a Student's t-Test. Asterisks (*) represent a statistical difference from control
(p<0.05).
3. Results
3.1. Serum BA concentration after BDL
Total BA concentrations in serum of mice that underwent
sham and BDL surgeries are shown in Fig. 1. Serum total BA
concentrations were 1–5 μmol/l in sham-operated mice and
were elevated to 1166, 1222, 2279, 2957 μmol/l at 1, 3, 7, and
14 days after BDL, respectively. One and 3 days after BDL,
serum BA levels increased approximately 200–250 fold abovethose detected in serum from sham mice. At 7 and 14 days after
BDL, serum BA concentrations were approximately 1800 fold
higher than that detected in sham mice.
3.2. Ntcp and Bsep mRNA expression in liver after BDL
Ntcp and Bsep are considered to be the primary BA
transporters in liver, and are responsible for hepatic uptake and
efflux of BAs, respectively. The effect of BDL on Ntcp and
Bsep mRNA expression in mouse liver is shown in Fig. 2. At 1
and 7 days after BDL, Ntcp mRNA expression was reduced
approximately 50%. Bsep mRNA levels in liver increased 40–
50% 1 and 7 days after BDL.
3.3. Oatp mRNA expression in liver and kidney after BDL
In liver, Oatps are thought to mediate sodium-independent
uptake of a wide variety of compounds, including bile acids.
The effect of BDL on Oatp mRNA expression in mouse liver is
shown in Fig. 3. BDL decreased Oatp1a1 and 1b2 mRNA
expression in liver. One day after BDL, Oatp1a1 mRNA
expression in liver was decreased by 80%, and by more than
90% thereafter. BDL doubled Oatp1a4 mRNA expression in
liver by day 3 and increased mRNA expression by 5 fold at
2 weeks. The mRNA expression of Oatp1b2, also known as
Liver-Specific Transporter (Lst), was decreased about 20% by
BDL. Basal mRNA expression of Oatp1a5 is relatively low in
rat liver [44], and BDL did not alter Oatp1a5 levels (data not
shown).
The effect of BDL on Oatp mRNA expression in mouse
kidney is shown in Fig. 4. BDL decreased renal Oatp1a1
expression by 50% on day 1, and about 90%, thereafter.
Oatp1a4 expression in kidney varied over time after BDL. After
BDL, Oatp1a4 mRNA expression in kidney increased at day 1,
did not differ from sham expression on day 3, and was
decreased at days 7 and 14. BDL doubled Oatp4a1 RNA
expression in kidney.
3.4. Mrp mRNA expression in liver and kidney after BDL
In liver, some multidrug resistance-associated proteins are
thought to transport BA and bilirubin–glucuronide out of
hepatocytes into bile or blood, namely Mrp3 [8]. The effect of
BDL on Mrp mRNA expression in mouse liver is shown in Fig.
Fig. 3. Time course of organic anion transporting polypeptide (Oatp) 1a1, 1a4,
1a5, and 1b2 mRNA expression in mouse liver after bile-duct ligation (BDL).
Total RNA was isolated from mouse livers collected 1, 3, 7, and 14 days after
sham or bile-duct ligation (BDL) surgery and analyzed by the bDNA assay for
organic anion transporting polypeptide (Oatp) 1a1, 1a4, 1a5, and 1b2
expression. The data are presented as mean relative light units (RLU)+S.E.M.
(n=4–7 animals). Asterisks (*) represent a statistical difference (p<0.05) bet-
ween sham and BDL groups.
Fig. 2. Time course of Sodium taurocholate-cotransporting polypeptide (Ntcp)
and Bile salt export pump (Bsep) mRNA expression in mouse liver after bile-
duct ligation (BDL). Total RNAwas isolated from mouse livers collected 1, 3, 7,
and 14 days after sham or BDL surgery and analyzed by the bDNA assay for
Ntcp and Bsep expression. The data are presented as mean relative light units
(RLU)+S.E.M. (n=4–7 animals). Asterisks (*) represent a statistical difference
(p<0.05) between sham and BDL groups.
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BDL in liver. At 1 day after BDL, Mrp3 andMrp5 mRNA levels
were elevated 1.4 and 3 fold, respectively. At 3 days after BDL,
Mrp1, 3, 4, and 5 mRNA expression was increased by at least
40% in livers from mice that underwent BDL surgery. At 7 and
14 days after BDL, mRNA expression of Mrps1–5 in liver was
significantly higher than that detected in livers from mice that
underwent sham surgery. All of the Mrps were increased 2 to 10
fold 7 and 14 days after BDL.
The effect of BDL on Mrp mRNA expression in mouse
kidney is shown in Fig. 6. BDL also increased Mrp mRNA
expression in kidney. Mrp2 and 4 mRNA expression was
significantly increased 1 day after BDL (30 and 50%,
respectively). BDL increased Mrp3 and 4 mRNA expression
3, 7, and 14 days after BDL. Mrp5 expression in kidney was
also doubled 7 days after BDL.
3.5. Transporter mRNA expression in intestine after BDL
The function of Ibat is to aid in absorption of bile acids from
intestinal lumen into enterocytes, and Mrp3 may participate in
export of BA from enterocytes into blood. The effect of BDL on
the expression of the bile acid transporters, Ibat in ileum and
Mrp3 in duodenum and ileum, is shown in Fig. 7. Ibat mRNA
expression in duodenum was very low (data not shown), but
was high in ileum. Ibat mRNA expression in ileum approxi-
mately doubled 7 and 14 days after BDL. BDL did not affect
Mrp3 expression in duodenum, but did increase Mrp3
expression in ileum. Mrp3 mRNA expression increased by
50% in ileum 14 days after BDL.
3.6. Mrp1–6 protein expression in liver after BDL
Mrp1–6 protein expression after BDL was measured in
liver membrane fractions (Fig. 8). BDL increased Mrp1, 3, 4,and 5 protein expression in mouse liver. Mrp1 expression in
liver was increased by 3.5 and 2.8 fold over sham controls at
3 and 7 days after BDL, respectively. Mrp2 protein levels
were slightly increased 1 day after BDL, but unchanged at 3
and 7 days after BDL. Mrp3 protein expression was in-
creased 6.6 and 12.4 fold over sham controls at 3 and 7 days
after BDL, respectively. Mrp4 protein expression was
increased 2.5 and 3.1 fold over sham controls at 3 and
7 days after BDL, respectively. Mrp5 protein expression was
increased 5.5 and 6.6 fold over sham controls at 3 and 7 days
after BDL, respectively. BDL did not affect Mrp6 protein
levels.
3.7. Induction of Heme Oxygenase-1 (Ho-1) mRNA and protein
expression in liver after BDL
Heme Oxygenase-1 is a microsomal enzyme that catalyzes
the conversion of heme to biliverdin, the precursor to bilirubin.
The Ho-1 gene is inducible and is known to be induced through
activation of the nuclear receptor, NF-E2-related factor-2 (Nrf2)
[45]. Fig. 9 illustrates the time course of Ho-1 expression in
liver after BDL. BDL induced Ho-1 mRNA expression in
mouse liver by about 2–5 fold at 1, 3, 7, and 14 days. Similarly,
Fig. 5. Time course of Multidrug resistance-associated protein (Mrp) 1–
5 mRNA expression in mouse liver after bile-duct ligation (BDL). Total RNA
was isolated from mouse livers collected 1, 3, 7, and 14 days after sham or BDL
surgery and was analyzed by the bDNA assay for Mrp expression. The data are
presented as mean relative light units (RLU)+S.E.M. (n=4–7 animals).
Asterisks (*) represent a statistical difference (p<0.05) between sham and BDL
groups.
Fig. 4. Time course of organic anion transporting polypeptide (Oatp) 1a1, 1a4,
1a5, 1a6n and 4a1 mRNA expression in mouse kidney after bile-duct ligation
(BDL). Total RNA was isolated from mouse kidneys collected 1, 3, 7, and
14 days after sham or BDL surgery and was analyzed by the bDNA assay for
Oatp 1a1, 1a4, 1a5, 1a6, and 4a1 expression. The data are presented as mean
relative light units (RLU)+S.E.M. (n=4–7 animals). Asterisks (*) represent a
statistical difference (p<0.05) between sham and BDL groups.
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3 and 7 days.
4. Discussion
It is important to understand changes that occur during
cholestasis at the molecular level. Understanding of how the
liver and kidney adapt in order to decrease tissue bile acid levels
is particularly important for understanding the pathophysiology
of cholestasis, and how drug distribution may be changed
during cholestasis. The goal of this study was to provide a
thorough characterization of the effects of BDL on hepatic,
renal, and intestinal transporter expression in mice. Given the
growing availability of knock-out mice and completion of
sequencing for the mouse genome, the mouse is becoming an
even more important model for studying gene expression and
function, as well as certain disease states. Therefore, identifying
changes in mRNA expression of genes in mouse tissuesimportant for transporting endogenous and exogenous com-
pounds by the liver, kidney, and intestine in mice during BDL,
is important for gaining insight into how tissues adapt to high
levels of bile acids, bilirubin, and other chemicals, as well as
how drug distribution could be changed during obstructive
cholestasis.
In this study, serum BA levels increased 1, 3, 7, and 14 days
after BDL. The level of BA in serum was markedly elevated
14 days after BDL. The continued elevation of serum BA levels
after BDL over 14 days suggests that BA production/transfer to
blood is occurring faster than renal excretion of BAs from the
blood and excretion into urine. Upregulation of Ibat, Mrp3, and
Ostα/β in ileum, and thus increased BA absorption from gut,
could also add to the observation of elevated serum BA levels in
mice throughout 14 days of BDL. These data also imply that
adaptive changes in liver, kidney, and intestine after BDL are not
sufficient to compensate for the decreased excretion of BA into
Fig. 6. Time course of Multidrug resistance-associated protein (Mrp) 1–
5 mRNA expression in mouse kidney after bile-duct ligation (BDL). Total RNA
was isolated from mouse kidney at 1, 3, 7, and 14 days after sham or BDL
surgery and was analyzed by the bDNA assay for Mrp 1–5 expression. The data
are presented as mean relative light units (RLU)+S.E.M. (n=4–7 animals).
Asterisks (*) represent a statistical difference (p<0.05) between sham and BDL
groups.
Fig. 7. Time course of Ileal bile acid transporter (Ibat) and Multidrug resistance
protein 3 (Mrp3) mRNA expression in mouse duodenum and ileum after bile-
duct ligation (BDL). Total RNA from duodenum and ileum was isolated from
mice 1, 3, 7, and 14 days after sham or BDL surgery and analyzed by the bDNA
assay for Ibat and Mrp3 expression. The data are presented as mean relative light
units (RLU)+S.E.M. (n=4–7 animals). Asterisks (*) represent a statistical
difference (p<0.05) between sham and BDL groups.
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14-day interval. The observation that BDL increases serum BA
levels is consistent with a previous report that demonstrated
elevations in serum total BA levels 3 and 7 days after BDL in
mice [18]. Interestingly, the observed increase in serum BA
levels after BDL in mice differs from results after BDL in rats in
which serum BA peaked 3 days after BDL, and declined
thereafter [46]. There are several possible reasons for this
observed species difference. First, the presence of a gallbladder
in mice may affect the concentration and amount of BA that the
liver is exposed to over time. Initially, the gallbladder in mice,
compared to rats, may act as a reservoir for BA, decreasing the
exposure of liver to high concentrations of BA. Bile flow rates
do not differ significantly between rats and mice [47]. Because
rats lack gallbladders, it is likely that after BDL, rat liver is
exposed to higher concentrations of BA and other bile
constituents at an earlier time than mouse liver. Second, the
composition of bile acids for rats andmicemay be different, suchthat rat BA are better signaling molecules for factors (such as
nuclear hormone receptors) that can affect Cyp7a (bile acid
formation) and transporter expression. Third, differences in
response elements in the upstream regulatory regions of genes
for the various transporters may exist between rats and mice,
such that the rat response elements are more markedly activated
or repressed. An example of this is Mrp3 induction in liver after
BDL in rats and mice. In rats, Mrp3 mRNA expression is
induced approximately 6 fold, but in mice Mrp3 mRNA is only
induced about 2–3 fold, 7 days after BDL [18,36]. The mRNA
and protein data in this study supports this finding. Thus,
changes in liver, kidney, and intestinal expression of transporters
that can transport BA after BDL observed in this study, in part,
explain how BDL increases serum bile acids in mice.
BAs are extracted from blood into liver via several known
transporters, including Ntcp and several Oatps. The role of
Oatps in renal absorption of bile acids is not defined. In the
present study, BDL altered the expression of several mouse
Oatps in liver and kidney. Mouse Oatp1a1 can transport
taurocholate and rat Oatp1a1, 1b2, and 4a1 can transport bile
acids. The data in this manuscript show that Ntcp, Oatp1a1, and
Oatp1b2 mRNA expression in liver are all markedly decreased
after BDL. In particular, BDL decreased Oatp1a1 mRNA
expression in liver by 93%. If the decrease in hepatic mRNA
expression of Ntcp, Oatp1a1, and Oatp1b2 causes a correspond-
ing decrease in hepatic protein expression, this could, in part,
explain the increased serum BA levels because the transporters
would extract less BA from blood into liver.
Fig. 8. Time course of Mrp1–6 protein expression in liver crude membrane fractions after bile-duct ligation (BDL). Upper panel: crude membrane fractions were
isolated from livers of mice 1, 3, 7, and 14 days after sham or BDL surgery and analyzed by Western blot analysis for Mrp1–6 expression. Lower panel: quantification
of Western blots. The data are presented as Fold Increase+S.E.M. (n=4–7 animals). Asterisks (*) represent a statistical difference (p<0.05) between sham and BDL
groups.
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protein expression was increased after BDL. It is unclear how
induction of these transporters may affect BA levels in serum and
liver after BDL. It is not knownwhether Oatp1a4 canmediate BA
uptake into liver or efflux out of liver. Whereas it is accepted that
Oatp1a4 transports some xenobiotics (i.e. cardiac glycosides)
into liver, it is unclear whether it also transports BAs into liver. A
recent publication has suggested that human OATP8/1B3 acts as
an efflux pump that symports with glutathione to extrude organic
anions from liver [48]. Thus, during cholestasis, Oatp1a4 may
serve a function similar to OATP8/1B3. However it has been
shown that Oatp1a4 has a relatively low affinity for taurocholate
so it is possible that induction of Oatp1a4 will have little or no
effect on BA levels in serum or liver after BDL. An alternate
explanation is that induction of Oatp1a4 is hepatoprotective
because induction of Oatp1a4 may increase BA transport into
liver, which in turn, may increase BA hydroxylation byCytochrome P450 3a11 (which is also upregulated after BDL),
and subsequently detoxifies the BA.
In the present study, BDL altered the mRNA and protein
expression of several mouse Mrps in liver, kidney, and intestine.
Mrps are efflux pumps in liver, transporting compounds such as
bile acids as well as glucuronide, glutathione, and sulfate-
conjugated compounds from liver into bile, and from liver into
blood. Bile acids are predominantly eliminated from hepato-
cytes into bile via Bsep and Mrp2, or out of hepatocytes into
blood via Mrp3, Mrp4, or Ostα/β, which are localized to the
basolateral membrane of hepatocytes and transport bile acids
out of hepatocytes into blood. Mrp3- and 4-null mice have been
used to study the contribution of these transporters during
obstructive cholestasis. Data regarding the role of Mrp3 in BA
disposition during cholestasis is somewhat unclear due to
conflicting studies—one reported that serum BA levels do not
differ in Mrp3-null mice [49], whereas another study reported
Fig. 9. Time course of Heme Oxygenase (Ho-1) mRNA and protein expression
in mouse liver after bile-duct ligation (BDL). Upper panel: total RNA from liver
was isolated from mice 1, 3, 7, and 14 days after sham or BDL surgery and
analyzed by the bDNA assay Ho-1 expression. The data are presented as mean
relative light units (RLU)+S.E.M. (n=4–7 animals). Asterisks (*) represent a
statistical difference (p<0.05) between sham and BDL groups. Lower panel:
crude membrane fractions were isolated from livers of mice 1, 3, 7, and 14 days
after sham or BDL surgery and analyzed by Western blot analysis for Ho-1
expression. The data are presented as fold increase+S.E.M. (n=4–7 animals).
Asterisks (*) represent a statistical difference (p<0.05) between sham and BDL
groups.
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induced liver injury was more severe and serum BA levels were
lower in Mrp4-null mice [35]. The data in this study show that
Mrps1, 3, 4, and 5 in mouse liver and kidney are induced after
BDL. BDL induced Mrp1 and 5 mRNA expression approxi-
mately 5 fold, and Mrp 3 and 4 mRNA expression
approximately 3 fold in liver. In kidney, among the Mrps,
Mrp3 was the most highly induced (approximately 3 fold). BDL
also increased Mrp1 and 3–5 protein levels in liver, whereas
Mrp2 and Mrp6 protein levels were not significantly changed.
These findings in mice are consistent with a previous report that
documents elevation of Mrp3 and Mrp4 mRNA and protein
levels in liver after BDL [18]. The data in this study demonstrate
a slight induction of Mrp2 in mouse kidney 1 day after BDL,
which was similar to a study that showed BDL increased Mrp2
expression in rat kidney 1 day after BDL [46,50]. In this study,
Mrp2 mRNA levels in liver were unchanged after BDL and
slightly increased 7 and 14 days after BDL. Mrp2 protein levels
were not markedly changed at 1, 3, or 7 days after BDL. A
previous report demonstrated that in mice, Mrp2 mRNA levels
in liver were slightly decreased 1 and 3 days after BDL and
similar to that detected in livers from sham-operated mice
7 days after BDL [18].
There are several mechanisms by which BA could regulate
gene expression. Bile acids can activate the nuclear hormone
receptors Farnesoid-X-receptor (FXR) and Pregnane-X-receptor(PXR) [51,52]. FXR is a “bile acid-sensor” and has a high
affinity for chenodeoxycholic acid (CDCA) [53], however,
CDCA levels in liver decrease after BDL [18]. However, FXR is
also activated in mice by cholic acid feeding [51], and BDL
increases cholic acid levels in livers of mice [18]. BA treatment
decreases Ntcp expression in vivo in an FXR-dependent manner
[51], and corresponds with suppression of protein binding to
RXR:RAR response element in the Ntcp promoter in vitro.
Lithocholic acid induces Oatp1a4 mRNA expression in mouse
liver in a PXR-dependent manner [52], however BDL decreases
lithocholic acid concentrations in mouse liver [18]. Thus, it is
unclear whether changes in transporter expression after BDL are
mediated via BA activation of FXR and PXR. Recently, Wagner
et al. reported that FXR expression was important for basal Bsep
andMrp4 expression, but not for Mrp3 and 4 induction in mouse
liver [18]. To date, there are no published studies that address the
role of FXR and PXR in transporter regulation after BDL in
kidney. It is possible that transporters in kidney and intestine are
regulated via activation of FXR and PXR, because both are
present in mouse kidney and intestine [54,55]. In addition to
FXR and PXR, the orphan nuclear receptor, Liver receptor
homolog-1 (Lrh-1, also named alpha fetoprotein transcription
factor) may also be important for induction of transporters in
liver and intestine after BDL, because Lrh-1 is activated in a
human intestinal cell line (Caco-2) by bile acids, and is
associated with induction of human Mrp3 [30]. In mice, Lrh-1
is expressed in liver, intestine, and colon, with relatively low
expression in kidney [56].
Data from the present study also demonstrates that BDL
increases the mRNA and protein expression of Ho-1, a
microsomal enzyme that catalyzes the conversion of heme to
biliverdin. The constitutive and inducible expression of Ho-1 is
dependent upon Nrf2 [45,57]. Thus, induction of Ho-1 mRNA
expression may indicate activation of Nrf2, which indicates a
novel pathway for regulation of transporter expression during
obstructive cholestasis. A recent study has described induction
of other Nrf2 target genes after BDL, namely NAD(P)H:
quinone oxidoreductase 1 [58]. In the present study, Mrp2
expression in liver was elevated at 7 and 14 days after BDL.
Recent publications demonstrate that mouse the mouse Mrp2
gene contains Nrf2-binding consensus sequences (antioxidant
response elements, AREs) that maintain basal Mrp2 expression
and mediate Mrp2 induction [59]. Thus, elevation of Mrp2 in
this model may be mediated through activation of Nrf2, and
increased binding of Nrf2 to AREs present in the mouse Mrp2
gene.
Bile duct ligation is also associated with inflammation. BDL
elevates serum levels of Interleukin-1 (IL-1), Interleukin-6 (IL-
6), and Tumor Necrosis Factor alpha (TNFα) in both rats and
mice [13,60]. TNFα has been implicated in the regulation of
Mrp3 expression in liver during cholestasis [13]. In TNFα
receptor-null mice, Mrp3 is not significantly induced after BDL,
and this lack of induction corresponds with Lrh-1 binding to
CPF/FTF/Lrh-1-response element in the mouse Mrp3 promoter
[13]. Elevated serum cytokines may also be involved in
mediating the alterations in kidney transporter expression after
BDL. A recent study also implicates a role for cytokines in
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(7 days) exacerbated acute renal failure and was associated with
elevation in serum IL-1 levels [61].
BDL decreased the mRNA expression of Ntcp, Oatp1a1,
1a5, and 1b2 in liver and Oatp1a1 in kidney. It has been
proposed that down-regulation of Ntcp and Oatps during
cholestasis is due to downregulation of the transcription
factors, hepatocyte nuclear factor 1 alpha (Hnf1α) [1]. Ntcp
expression in liver is down-regulated after lipopolysaccharide
treatment and obstructive cholestasis [31,62]. Downregulation
of Ntcp during obstructive cholestasis appears to be
cytokine-independent and occurs through decreased protein
expression of the Hnf1α and 4, transcription factors that
maintain basal Ntcp transcription [33,56]. Ablation of Hnf1α
expression affects the expression of a large number of genes
in liver, and markedly decreases expression of Oatp1a1 and
Oatp1b2 [63,64]. In human cultured hepatoma cells, CDCA
treatment decreased Hnf1α expression [65]. Because Hnf1α
is also expressed in kidney, it is possible that the observed
decrease in renal Oatp1a1 mRNA expression after BDL is
due to decreased Hnf1α expression and/or binding to the
Oatp1a1 promoter [66].
It could be speculated that during obstructive cholestasis, the
liver, kidney, and intestine will alter gene and protein expression
to lower serum levels of BA and enhance BA excretion into
urine to ultimately protect the organism. However, the data
presented in this study suggest that this compensation is not
adequate. For the most part, gene expression changes in liver
and kidney are in a manner consistent with decreasing the
cellular BA concentrations in those organs. Changes in
transporter expression in liver, kidney, and intestine during
extrahepatic cholestasis may not only be important for handling
excess bile acid levels in tissues, but also for the disposition of
drugs that are substrates for the Oatp and Mrp families of drug
transporters. In conclusion, BDL altered the gene expression for
Ntcp, Bsep, and members of the Mrp and Oatp family in mouse
liver and/or kidney.
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